Health Canada granted approval for Macugen (pegaptanib sodium injection) for the treatment of subfoveal choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (‘wet’ AMD). Macugen is the
The phosphate-binding affinity of Fosrenol (lanthanum carbonate) was more than 200 times higher compared to sevelamer HCl (marketed by Genzyme as Renagel) at pH 3, which simulates the
The triglyceride-lowering effects of MC-1 were evaluated in an industry-standard cholesterol model. The in-vivo model involves feeding a high cholesterol diet to the subject animals thereby inducing high
NephroGenex has acquired exclusive commercial rights to the glomerular transcriptome profiling technology developed by doctors at the world-renowned Karolinska Institute in Stockholm, Sweden. This technology utilizes GlomChip, a
This indication concerns the use of tetrahydrobiopterin (6R-BH4) as a treatment for the endothelial dysfunction that causes vascular complications in diabetes, cardiovascular and other diseases. The newly acquired
Lovenox, an enoxaparin sodium injectable product, is indicated for the prevention of deep vein thrombosis in certain patients undergoing abdominal surgery and knee or hip replacement surgery, and
The primary endpoint for this Corlux (mifepristone) phase III trial, known as Corcept 09, is the proportion of patients with at least a 50% improvement in the brief
VaxGen intends to fund proof-of-concept studies during the next 12 months and has an exclusive option to continue product development if the studies yield promising results. The initial
The acquisition of Bone Care will bring Genzyme a complementary line of products and a profitable commercial organization that will strengthen and diversify its renal business. Bone Care’s
OncoVex (GM-CSF), BioVex’ lead product candidate for the treatment of solid tumors, is an oncolytic virus that selectively kills tumor cells. It also induces tumor cells to secrete
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.